header logo image


Page 171«..1020..170171172173..180190..»

The roles of immune system and autoimmunity in pulmonary arterial hypertension: A Review – DocWire News

November 7th, 2021 1:55 am

This article was originally published here

Pulm Pharmacol Ther. 2021 Nov 2:102094. doi: 10.1016/j.pupt.2021.102094. Online ahead of print.

ABSTRACT

Pulmonary arterial hypertension (PAH) is a chronic disease characterized by increased pulmonary artery pressure which if left untreated, can lead to poor quality of life and ultimately death. It is a group of conditions and includes idiopathic PAH, familial/hereditary PAH and associated PAH. The condition has been studied for many years and its association with the immune system and in particular autoimmunity has been investigated. The mechanisms for the pathobiology of PAH are unclear although research has highlighted the role of adaptive and innate immune systems in its development. Diagnostics and therapeutic approaches range from cytokine treatments to the use of immunomodulating drugs, although there is still scope for improvements in the field. This article discusses the mechanisms linked to PAH, its association with other conditions and recent therapeutic interventions.

PMID:34740751 | DOI:10.1016/j.pupt.2021.102094

Originally posted here:
The roles of immune system and autoimmunity in pulmonary arterial hypertension: A Review - DocWire News

Read More...

Thanks to Mice, We May Know Why Arthritis Keeps Flaring Up in The Same Joints – ScienceAlert

November 7th, 2021 1:55 am

When the debilitating effects of rheumatoid arthritis (RA) come on, it tends to happen in the same joints that have previously been stiff, swollen, or in pain before and that remains the case even if there's a long time between each flare-up.

According to new research conducted on mice, this could be because our immune system keeps a record of these past afflictions, creating a personalized disease pattern in each individual. Understanding more about how and why this happens could open up new opportunities for treating the disorder.

This latest study zooms in on the T cells in mice's bodies, white blood cells that are key to the immune system. In particular, the T cells in the synovium the tissue lining the inside of the capsule around each joint appear to hold a memory of previous RA problems.

"Overwhelmingly, flares occur in a previously involved joint," says immunologist Peter Nigrovicfrom Boston Children's Hospital. "Something in that joint seems to remember, 'this is the joint that flared before'."

"We showed that these T cells anchor themselves in the joints and stick around indefinitely after the flare is over, waiting for another trigger. If you delete these cells, arthritis flares stop."

This was demonstrated through two mouse models using chemical triggers to cause joint inflammation and one mouse model using a genetic trigger to generate the same effect: The researchers removed a protein that blocked the pro-inflammatory cytokine IL-1.

These triggers caused T cells to rally other cells to the immunity cause, leading to arthritis flare-ups in specific joints in the mice. When these T cells were taken out, additional inflammation was prevented. These T cells don't move between joints and take up "long-term residency" where they are, the researchers say, ready to be reactivated again.

The approach taken here was actually inspired by skin studies. T cells with a form of memory are known to reside in the skin, leading to repeating patterns in skin problems such as psoriasis. It also happens with reactions to nickel in jewelry or wristwatches.

"A person reacting to nickel through a belt buckle may also develop a rash on their wrist, where they wore a nickel-containing watch as a child," says Nigrovic.

The team thinks that other types of autoimmune arthritis could work in the same way, which could lead to better treatments and approaches to these issues. The next step is to confirm that the same process happens in humans and find out ways to target it.

It's possible that other mechanisms are also playing a part in this RA memory retention, the researchers say it could be that T cells are the main cause in some cases but not others. That's something that further studies in the future should be able to analyze.

With millions of people affected by rheumatoid arthritis across the world, any kind of alleviation of pain or management of symptoms is going to be welcome. The good news is that scientists are constantly discovering more about how the disorder operates.

"Right now, treatment of rheumatoid arthritis has to continue lifelong," says Nigrovic. "Although we can successfully suppress disease activity in many patients, there is no cure. We think our findings may open up new therapeutic avenues."

The research has been published in Cell Reports.

The rest is here:
Thanks to Mice, We May Know Why Arthritis Keeps Flaring Up in The Same Joints - ScienceAlert

Read More...

Natural vs. vaccine immunity and what a disease immunologist says about the science – News 5 Cleveland

November 7th, 2021 1:55 am

CLEVELAND Weve heard many questions come up in the last several months about natural immunity and whether its enough to protect those who have it from COVID-19, in lieu of a vaccine.

The topic came up last month at the Ohio Statehouse, where some lawmakers tried to get natural immunity added as an exemption to vaccine mandates.

Dr. Mark Cameron, a disease immunologist at Case Western Reserve University, spoke with News 5 on Friday to answer questions about natural immunity, vaccine-mediated immunity and what all of this means for individuals and their physicians.

Cameron said the number of new COVID-19 daily cases in Ohio has been coming down for a while.

We're winning the skirmishes, I would say, against this virus at the moment. But are we winning the war ultimately? Cameron said, noting that flu season coming up poses additional complications.

He started with some definitions of phrases weve all heard thrown around.

Natural immunity refers to being infected with COVID-19 and going through the disease process and clearing the virus, gaining a level of immunity over it, Cameron said. Also in the short term, we don't know how long with COVID-19, being immune to reinfection for a certain length of time.

A natural infection and gaining immunity to COVID-19 by having it before certainly provides your immune system with enough instruction, enough education to avoid reinfection with COVID-19 again, he added.

All of this is different from (but works the same as) vaccine-mediated immunity, where you gain that immunity through the shot, through the vaccine.

Cameron said there is a similar mechanism for your body between natural immunity and immunity gained by the vaccine, even though youre getting it a different way.

This is a means of preventing reinfection through neutralizing antibody levels to the spike protein, and that blocks, as long as they're present and you know, plentiful enough, that blocks the virus from getting back into your cells and making you sick, Cameron said.

The standard test by which to check levels of someones antibodies to anything (a viral infection, a vaccine, etc.) is to do a titer check, where they actually test levels of antibodies against a given infectious agent.

With COVID-19, Cameron said, since there could be a natural infection from other types of coronaviruses, those antibody tests may not be entirely clear.

Even if we can be very specific to the coronavirus that causes COVID-19, we don't yet know what the particular levels are required to be successful in blocking it in the future, Cameron said. It varies very greatly between individuals, and it also varies over time as we are coming fully to grip now in this idea of waning immunity.

Waning immunity, Cameron cautioned, doesnt mean your immune system cant reboot and help you recover from reinfection by COVID-19. But he said COVID-19 is very good at getting in and getting ahead of our immune system and infecting us, so we need high levels of neutralizing antibodies so that the virus barely gets a chance to enter our cells.

OK so there are a lot of questions to which we still dont have answers. Such as, if someone has already had COVID-19, whats the long-term risk of getting it again? Or, if theyre vaccinated and get a breakthrough case, can we say if their immune system responded to the vaccine in the first place?

However we gain immunity to COVID-19, our immunity drops over time. That really is dependent on that neutralizing antibody level and whether we got COVID-19, whether we had the full vaccine regimen, whether we had both conditions, we will need a boost as well over time, Cameron said.

He emphasized it is hard to come up with a common piece of advice that covers everyone.

I certainly understand those concerns and really that comes down to yourself and your physician, Cameron said. There may be very good reason, you know, in consulting with your doctor why you wouldn't get a boost now or you wouldn't get the vaccine right now if you indeed didn't have it, you know, in the past. And that could be because you had COVID-19 very recently. It could be that you're sick with another infectious disease and your immune system is already activated. Or it can be the opposite where somebody is immunosuppressed or they are on cancer treatments and other type of therapies where your immune system is essentially kicked when it's down.

All of these, he said, are important considerations to take up with ones doctor. However, he was clear that the overall science supports getting a vaccine even if you have natural immunity from COVID-19 already.

Natural infection by COVID is is certainly not a safe way to gain immunity to this virus. And really, I would say that risking reinfection isn't either, he said.

He added, We are more prepared than ever to clear this infection or at least stop it from hurting and killing us like it has in the past.

Download the News 5 app for free to easily access local coronavirus coverage, and to receive timely and limited news alerts on major COVID-19 developments. Download now on your Apple device here, and your Android device here.

See complete coverage on our Coronavirus Continuing Coverage page.

Vaccinating Ohio - Find the latest news on the COVID-19 vaccines, Ohio's phased vaccination process, a map of vaccination clinics around the state, and links to sign up for a vaccination appointment through Ohio's online portal.

See data visualizations showing the impact of coronavirus in Ohio, including county-by-county maps, charts showing the spread of the disease, and more.

Rebound Northeast Ohio News 5's initiative to help people through the financial impact of the coronavirus by offering one place to go for information on everything available to help and how to access it. We're providing resources on:

Getting Back to Work - Learn about the latest job openings, how to file for benefits and succeed in the job market.

Making Ends Meet - Find help on topics from rent to food to new belt-tightening techniques.

Managing the Stress - Feeling isolated or frustrated? Learn ways to connect with people virtually, get counseling or manage your stress.

Doing What's Right - Keep track of the way people are spending your tax dollars and treating your community.

We're Open! Northeast Ohio is place created by News 5 to open us up to new ways of thinking, new ways of gathering and new ways of supporting each other.

View a map of COVID-19 testing locations here.

Visit Ohio's Coronavirus website for the latest updates from the Ohio Department of Health.

View a global coronavirus tracker with data from Johns Hopkins University.

Go here to read the rest:
Natural vs. vaccine immunity and what a disease immunologist says about the science - News 5 Cleveland

Read More...

Research Explores How Covid-19 Alters The Immune System – NDTV Doctor

November 7th, 2021 1:55 am

Researchers found that Covid-19 might cause the immune system to react less strongly than expected to bacterial or other viral infections following recovery from COVID-19, but this possibility will require further clinical investigation.

Covid 19 can adversely impact the immune system

Ludwig Maximilian University of Munich researchers say that COVID-19 reduces the numbers and functional competence of certain types of immune cells in the blood.

This could affect responses to secondary infections. The findings were published in the journal PLOS Pathogens.

The SARS-CoV-2 coronavirus causes moderate to severe disease in 3-10 per cent of those infected. In such cases, the immune system overreacts to the virus, triggering an aberrant innate immune response that is characterized by systemic inflammation, intravascular blood clotting and damage to the cardiovascular system.

A team led by immunology professor Anne Krug at LMU's Biomedical Center (BMC), which included many researchers based at the BMC and the LMU Medical Center, has carried out a comprehensive study of this phenomenon and uncovered hitherto unknown effects of the virus on the immune system.

In the journal PLOS Pathogens, they report that, following infection with SARS-CoV-2, the numbers of immune cells called dendritic cells in the circulation decline, while the functionality of the remaining fraction is impaired.

The authors believe that this could make patients more susceptible to secondary infections during, and immediately after recovery from a bout of COVID-19.

Dendritic cells (DCs) are responsible for initiating immune responses against invasive pathogens. They do so by activating helper T cells, which in turn stimulate B cells to secrete antibodies directed against the invader. Krug and her colleagues set out to determine the effects of moderate to severe coronavirus infection on this process. They analyzed blood samples obtained from 65 COVID-19 patients who had been treated at the LMU Medical Center.

They found that there were fewer DCs in these samples than in the blood of healthy controls. Furthermore, DCs isolated from the blood of patients showed a reduced ability to activate T cells.

"We had actually expected that DCs isolated from patients infected with SARS-CoV-2 would activate T cells more potently than DCs obtained from healthy donors," says Krug.

"However, we discovered that, in the course of the disease, the proteins present on the surface of the DCs in patients' blood were altered in a way that made them more likely to inhibit T cell responses." In spite of this, by 15 days after diagnosis 90 per cent of these patients had generated antibodies directed against the SARS-CoV-2 spike protein, and many of them had also activated a T cell response. - these responses are the hallmarks of a robust immune reaction against the virus. "So, the drop in the numbers and reduced functionality of DCs does not seem to have a negative impact on the immune response to the coronavirus itself," Krug says.

However, she is convinced that the reduced number and altered function of DCs is significant. It is conceivable that this might cause the immune system to react less strongly than expected to bacterial or other viral infections following recovery from COVID-19, but this possibility will require further clinical investigation.

What might account for the depletion of DCs in the blood and the decrease in their capacity to stimulate T cells? - Krug has several hypotheses to offer. It could in fact represent an appropriate regulatory process, she suggests. COVID-19 is often associated with vigorous inflammation reactions - so the phenomenon might be part of an attempt to downregulate inflammatory processes.

Dendritic cells might migrate from the blood into inflamed tissues, such as the lung, which could explain the fall in the numbers of DCs in the circulation. "However, we also found that the regeneration of dendritic cells is delayed," Krug points out.

The authors of the study believe that this phenomenon could weaken the ability of patients to mount effective immune responses to other pathogens during, and in the immediate aftermath of asymptomatic COVID-19 infection. The team will now explore this issue further in an effort to determine whether the effects of SARS-CoV-2 on DCs play a role in long-term COVID.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

See the article here:
Research Explores How Covid-19 Alters The Immune System - NDTV Doctor

Read More...

COVID-19 Vaccines For Kids And Adults: How Your Immune System Changes As You Mature, Immunologist Explains – TheHealthSite

November 7th, 2021 1:55 am

Vaccines work differently for different people based on their age group. Here we have an immunologist to talk about why vaccines for kids and adults are different.

Written by Satata Karmakar | Published : November 4, 2021 11:19 AM IST

Human beings are born pretty helpless, with a lot of developing to do. And just as you must learn such skills as how to walk, so must your immune system learn to defend against infections. As time passes, your immune system matures through different stages, much the way you advanced from crawling to standing, walking, and running. This process is one of the reasons scientists study the immune response to a vaccine in different age groups, and why, for example, the COVID-19 vaccines need to be tested separately in children ages 5-11 and those 12-16.

Doctors want to use the vaccine dose that provides the best protection with the fewest side effects. And that's going to depend on how the immune system is working based on how developed it is something you can't really tell from the outside. I'm an immunologist, and here's the way I explain to my pediatric and adult patients how vaccines work in people of all different ages.

The immune maturing process starts shortly after birth. When you're born, your main immune protection comes via antibodies your mother shared through the placenta and breast milk. They provide what's called passive immunity.

Newborns' adaptive immune system the part of your immune system that will make your own antibodies isn't really up and running yet. The process gets started right away, but it can take years for the adaptive immune system to reach full maturity.

Luckily you're also born with what's called the innate immune system and it lasts throughout your life. It doesn't need to learn in order to fight off infections and promote health as the adaptive immune system does. Without the innate immune system, people would get sick a lot faster and more often.

The innate immune system starts with your skin and mucous membranes. Should any germs get past those physical barriers, it has enzymes just waiting to break down foreign organisms. Beyond that, there are specialized cells looking for anything that is not you in order to kill intruders, while other cells called phagocytes gobble up invaders. So the innate immune system is your body's first responder. It buys you a bit of time. Then your adaptive immune system comes in and joins the fight.

When you become immunized via a vaccine or infection, your adaptive immune system starts actively making antibodies of your own. They're proteins that act like suction cups and stick to viruses or bacteria to help the body get rid of the germs faster and prevent the infection from spreading. Antibodies are specialized to recognize and take down a particular intruder. The adaptive immune system can learn a new infection or recall one that it has not seen in a long time.

In the same way, an infant will learn to walk even if you don't secure the stairways and pool areas for them, your immune system can learn to squelch an invading virus without a vaccine but the chance of injury is much greater.

Vaccines work by triggering the creation of antibodies that will recognize a specific germ and work to fight it off in a safer manner than getting the infection for the first time without it.

How well a vaccine works is a combination of how many antibodies you produce in response to it, how effective they are, and the safety of the vaccine.

When researchers work to fine-tune the dosage of a vaccine for different age groups, they need to be aware of what parts of the immune system are online and what parts aren't fully active in people at each developmental stage.

This is part of the reason some vaccines such as for COVID-19 get tested and approved on different schedules for adults, teens, kids, and babies.

A number of vaccines for infants are given as a series meaning they get the same kind of shot several times over the course of a few months. A baby's adaptive immune system is prone to being forgetful or not listening at this age the same way a baby falters as it tries to stand and walk.

With each exposure, every aspect of the immune system gets stronger and better at defending against the would-be infection.

After 4 years of age and through younger adult life, your immune system tends to be more responsive and less prone to forgetting. It's not a coincidence that this is when people tend to gain most of their allergies.

For the COVID-19 Pfizer vaccine, researchers found that kids ages 5 to 11 had a similar immune and safety response at one-third the dose used for those ages 12 and up.

Scientists tend to start with patients between ages 18 and 55 years old when studying vaccines. Their adult immune systems have matured and they can be counted on to reliably report any adverse reactions.

Seeing what happens in the adult age group also helps physicians predict what might occur when a vaccine is administered to others and be on the lookout for these side effects in the younger age groups.

(With inputs from Agencies)

Follow us on

Excerpt from:
COVID-19 Vaccines For Kids And Adults: How Your Immune System Changes As You Mature, Immunologist Explains - TheHealthSite

Read More...

The Final Verdict On Which Vitamins Actually Boost Your Immunity Eat This Not That – Eat This, Not That

November 7th, 2021 1:55 am

When cold and flu season comes around, tissues aren't the only thing we stock up on. Many of us rely on immune-boosting supplements that we either take throughout the season or whenever we feel a cold coming on to help lessen symptoms. While taking supplements isn't necessary if you have a well-balanced diet rich in whole foods and immune-supporting nutrients, it's always helpful to have the option of getting some virus-fighting reinforcements from vitamin supplements.

But have you walked down the supplement aisle recently? If so, you probably already know that there's no shortage of supplements that claim to support your immune health; however, what you may not realize is that there are only a few that are scientifically proven to do what they claim. We spoke to Mia Syn, MS, RDN, a South Carolina-based registered dietitian of Nutrition by Mia to identify which vitamins actually boost your immunity. Read on, and for more on how to eat healthy, don't miss 7 Healthiest Foods to Eat Right Now.

The sunshine vitamin plays a key role in brightening up your immune system."In addition to its critical role in calcium and bone homeostasis, vitamin D plays a key role in modulating the immune response," says Syn. Just how much of a role does vitamin D play in your immune response? "Vitamin D receptors are expressed on immune cells!" explains Syn, who adds that "deficiency in vitamin D is associated with increased susceptibility to infection."

What to buy: For the most effective immune-boosting vitamin D supplement, you're going to want to look for calcifediol: an active form of vitamin D. A calcifediol supplement does not need to be processed by the liver like a vitamin D2 or D3 supplement would (these are the more common types of vitamin D you'll see sold), so it can be absorbed directly into the bloodstream. This makes a calcifediol supplementthree times more effective in raising vitamin D levels when compared to vitamin D3.

RELATED: Sign up for our newsletter to get daily recipes and food news in your inbox!

Vitamin K2 is a fat-soluble vitamin that is most commonly associated with blood coagulation; however, that's not the only role it plays in the human body. This vitamin also modulates the immune response. "While vitamin D is vital for immune health, it is important to note that vitamin D supplementation is critically important in relation to vitamin K2. Vitamin K2's main role is to work with vitamin D to regulate the transport and distribution of calcium in the body to support heart and bone health. Without enough vitamin K2, osteocalcin remains inactive and calcium will not be integrated into our skeletal system which can lead to excess calcium that can be deposited in the cardiovascular system, where it can have harmful effects," says Syn.

What to buy: There are two different types of vitamin K, and it's important to understand that we're talking about vitamin K2, not K1. Vitamin K is a cofactor for anti-inflammatory proteins and vitamin K2 is more active than K1.

You guessed it! Everyone's favorite immune-boosting vitamin is on our list: "Vitamin C plays a critical role in supporting various cellular functions of both the innate and adaptive immune system. This includes supporting epithelial barrier function against potential invaders and accumulating on immune cells such as neutrophils to enhance microbial killing. Additionally, it may help shorten the duration of a common cold," says Syn.

What to buy: When you're looking for the best way to support your immune system with vitamin C, you're going to want to look for "liposomal vitamin C." Liposomal vitamin C is a form of vitamin C encapsulated in liposomes, which are essentially capsules that protect the vitamin C from digestive acids and enzymes that might break it down within the digestive tract. This makes liposomal vitamin C more bioavailable than your standard vitamin C from supplements.

READ MORE:The #1 Vitamin C Supplement to Take, Says Dietitian

It's time to load up on oysters! (Oh, that's because they're naturally rich in zincnot because it's happy hour.) "Zinc is needed to develop and activate immune cells and a deficiency is characterized by impaired immune function," says Syn.

What to buy: Look for zinc lozenges, not zinc supplements in pill form. The National Institutes of Health reports that zinc lozenges may help reduce symptoms of the common cold if taken with 23 hours of the start of symptoms, but more research is needed to determine the most effective dose.

Read this next:

More:
The Final Verdict On Which Vitamins Actually Boost Your Immunity Eat This Not That - Eat This, Not That

Read More...

Vaccinated individuals infected with Covid-19 showed immune response boost: S’pore study – The Straits Times

November 7th, 2021 1:55 am

SINGAPORE - Individuals vaccinated against Covid-19 but who still caught the virus showed an "excellent boost" intheir immune response, a study by local researchers has found.

The findings are based on researchers checking the antibody levels of 150 people from Singapore who had breakthrough infections.

Dr Barnaby Young of the National Centre for Infectious Diseases (NCID) told The Straits Times the individuals' immune memory had kicked in within a few days of being infected.

This meant they showed a strong immune response to the virus, said Dr Young, head of the Singapore Infectious Diseases Clinical Research Network at NCID.

All 150, who were recruited in May this year, had mild Covid-19 disease.

The study, which is ongoing, is being conducted by NCID, the Agency for Science, Technology and Research's Infectious Diseases Labs, and Duke-NUS Medical School.

Further studies will be conducted to look at their T-cell response as well, he added.

The immune response is shaped by both the level of neutralising antibodies, which bind with the virus and prevent it from infecting one's cells, and T-cells, which helps to clear infected cells.

Dr Young explained that having immune memory means the immune system is able to recall the antigens, which are molecules on the surfaces of virus, that it was previously exposed to.

With immune memory, the body might rapidly produce antibodies to stimulate a stronger immune response when the same virus or pathogen is encountered again.

"While the neutralising antibodies may bind to the wild-typevirus, the immune boost can help to neutralise the Delta variant, as the two are not drastically different," said Dr Young, who led the study.

Some of the findings have been published in a pre-print report, which has yet to be peer-reviewed.

"We expect the antibodies to help protect against infection for current circulating variantsand probably future unknown ones, too, though this would depend on how dramatically it changes from Delta," he added.

People waiting at the Covid-19 vaccination centre at Tanjong Pagar Community Club on Oct 12, 2021. ST PHOTO: JASON QUAH

Further studies will be needed to determine how quickly these antibodies will wane later on, and whether the level of antibodies will be strong enough to protect against future reinfections, said Dr Young.

The immune boost does not necessarily mean breakthrough infections will not occur again.

Professor Paul Tambyah, president of the Asia Pacific Society of Clinical Microbiology and Infection, said having high antibody levels may not always correlate with greater protection against infection.

"In fact, many individuals who were doubly vaccinated had high titres of antibodies yet developed symptomatic Covid-19 infection. The immune response is actually a lot more than just antibody levels," he added.

A titre is a measure of concentration.

Aside from the T-cell response, the immune response also comprises the innate immune response, which is the body's first line of defence against all antigens.

Antibodies can protect against most infections, such as hepatitis B and measles.

But "not so good" antibodies, which may be produced following vaccinations against the respiratory syncytial virus and possibly dengue, could lead to severe infections, he noted.

As for Covid-19, it is unclear whether those who had breakthrough infections would be protected against reinfection, given that current vaccines do not protect against infection very well, said Prof Tambyah.

In the best-case scenario, with a high vaccination rate and as more of the population is infected with Covid-19, the risk of severe disease will be low, said Prof Tambyah.

A previous Duke-NUS study done with NCID on survivors of the severe acute respiratory syndrome, or Sars,showed that they had a powerful antibody boost against a range of beta-coronaviruses when they were given a single dose of Covid-19 vaccine.

Natural infection and vaccination may provide long-lasting immunity, noted Prof Tambyah.

He added that some scientists believe Covid-19 booster jabs will be needed to protect against reinfection, like with hepatitis B, which requires three jabs.

Associate Professor Hsu Li Yang said certain vaccines require two or more doses to repeatedly trigger immunological memory through rapid production of antibodies -for instance, tetanus shots and the hepatitis B vaccine, as well as the vaccines protecting against Covid-19.

Even for single-dose inactivated vaccines, such as those for influenza, a second dose (or infection) will also boost antibody levels, noted Prof Hsu, who is vice-dean of global healthand infectious diseases programme leader at the National University of Singapore's Saw Swee Hock School of Public Health.

"Infection following shortly after vaccination, or vice versa, serves as an antigen challenge to the immune system, triggering a stronger response than if there were no prior exposure to the vaccine or infection," he said.

Read more from the original source:
Vaccinated individuals infected with Covid-19 showed immune response boost: S'pore study - The Straits Times

Read More...

Immune response of neonates born to mothers infected with SARS-CoV-2 – EurekAlert

November 7th, 2021 1:55 am

What The Study Did: This study of 21 mothers investigated the association of maternal SARS-CoV-2 infection with immune response in children in the first two months of life.

Authors: Rita Carsetti, M.D., of Bambino Gesu Children's Hospital in Rome, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2021.32563)

Editors Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text articleThis link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2021.32563?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110321

About JAMA Network Open:JAMA Network Open is thenew online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

JAMA Network Open

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more:
Immune response of neonates born to mothers infected with SARS-CoV-2 - EurekAlert

Read More...

NSCLC and COVID-19: Risks and precautions – Medical News Today

November 7th, 2021 1:55 am

People with non-small cell lung cancer (NSCLC) may have an increased risk of severe illness from COVID-19. Guidelines advise people with NSCLC to follow the same protocols as others to protect themselves from the virus while maintaining their treatment schedule and getting the vaccine when their doctor advises.

If a person with NSCLC gets a SARS-CoV-2 infection, they may be at higher risk of severe complications. Additionally, the effects of the pandemic may mean that there are delays to cancer treatment and screening. Health experts advise those with lung cancer to reduce their risk of infection and potential complications by following prevention methods, such as hand washing, mask wearing, physical distancing, and receiving the vaccine when possible.

Evidence suggests that the COVID-19 vaccines are safe and effective for individuals with NSCLC and that these shots can help lower their health risks. This is also true for people currently receiving cancer treatments, such as immunotherapy and chemotherapy. However, these individuals may require close monitoring to identify potential side effects. It is also advisable to consult a doctor regarding a suitable vaccine schedule.

This article discusses the associations between NSCLC and COVID-19, as well as the potential risks and appropriate precautions.

According to the American Cancer Society, lung cancer is among the most common forms of cancer in the United States and the leading cause of cancer deaths. There are two main types of lung cancer: NSCLC and small cell lung cancer. Approximately 84% of lung cancer cases are NSCLC, which can be difficult to treat, as it is often less sensitive to the current treatment options than other cancers.

People with NSCLC can experience symptoms that include:

People with NSCLC are also vulnerable to infection. This is because the combination of the disease and its treatments, such as chemotherapy, leads to a weakened immune system. People with cancer have a higher risk of severe illness from COVID-19.

COVID-19 is a respiratory disease that also affects the airways and lungs. The condition can cause symptoms similar to those of NSCLC, such as a persistent cough, tiredness, and breathing difficulties. Other symptoms of COVID-19 may include:

According to the Centers for Disease Control and Prevention (CDC), people with some chronic medical conditions, including cancer, are more likely than other people to develop a severe illness from COVID-19. Severe illness from COVID-19 can result in:

The increased risk for people with NSCLC can be due to the cancer itself, the cancer treatment, or a combination of both. People with NSCLC are also more likely to have other risk factors for severe illness from COVID-19, such as smoking and older age.

A 2021 review highlights evidence indicating that people with lung cancers are more likely than people with other cancers to die from COVID-19. A history of smoking and the increased pressure that the pandemic has placed on respiratory services in hospitals could contribute toward this increased risk.

Lung cancer can also cause various other complications, including blood clots, heart problems, and neuropathy.

There are many possible treatment options for people with NSCLC. These include:

The best type of treatment will depend on several factors, including the spread of the cancer and the presence of other medical conditions. Treatment will typically involve a combination of approaches.

COVID-19 has caused major disruptions to cancer care worldwide. A 2021 study suggests that the increased pressure on services during the pandemic is the main cause of these disruptions.

The treatment for NSCLC commonly involves visiting a clinic or hospital. This approach may put people with NSCLC at a higher risk of developing COVID-19 and potentially severe complications. The treatments themselves also pose additional risks by affecting the immune system. For example, chemotherapy suppresses the immune system, which reduces the bodys natural defenses against infections and disease.

People with NSCLC should discuss the risks and benefits of different treatment approaches in the context of COVID-19. In some cases, a doctor may suggest delaying treatment to minimize the risk of complications. They may also suggest that people receive a COVID-19 vaccine before initiating cancer treatments, as this may improve the chances of an adequate immune response.

COVID-19 vaccinations are a safe and effective way of preventing severe disease and limiting the spread of the virus that causes it. The CDC states that COVID-19 vaccines have been subject to the most intense safety monitoring in U.S. history.

Health experts recommend that people with most underlying medical conditions, including cancer, get the vaccine. The risks of COVID-19 are far greater for people with cancer than the risk of rare side effects from the vaccine.

However, it is important for people with cancer to discuss with a doctor when is the right time to receive the vaccination. Some cancer treatments suppress the immune system and may reduce the effectiveness of the vaccine. People who have recently received cancer treatment may benefit from waiting until their immune system fully recovers before getting the vaccine.

People with NSCLC should take additional care to avoid getting COVID-19 due to the increased risk of severe disease. The National Cancer Institute recommends that people with cancer, or a history of cancer, keep safe and minimize the risk of getting a SARS-CoV-2 infection by:

NSCLC is a serious condition that requires treatment from a doctor. Early detection is vital to catching the cancer before it spreads and to improving treatment outcomes. Anyone who experiences any symptoms of NSCLC should contact a doctor immediately.

People living with NSCLC should also contact a doctor if they notice potential symptoms of COVID-19. A doctor can advise on testing and whether to visit a clinic in person or organize a home visit.

NSCLC is a common form of lung cancer that can be fatal. As both the condition itself and its treatments can affect the immune system and lungs, lung cancer puts a person at increased risk of potentially severe complications of COVID-19. It is advisable for people with NSCLC to follow guidelines on avoiding the virus, which include receiving the vaccine.

Evidence suggests that the vaccine is safe for people with NSCLC and that it can help provide adequate protection against SARS-CoV-2. A doctor can advise when to schedule a vaccine, which may be best before or after cancer treatments, so that it provides the optimal immune response.

Original post:
NSCLC and COVID-19: Risks and precautions - Medical News Today

Read More...

Healthy Living: Autoimmunity the confused immune system – Limerick Leader

November 7th, 2021 1:55 am

I hate to be the voice of doom, but on top of the pandemic we are also facing an epidemic of allergic, asthmatic, and autoimmune disorders. You might be familiar with the first two, but when it comes to autoimmunity, most people only hear about it when they receive a diagnosis. It is certainly becoming one of the most common health concerns clients come to my clinic.

Autoimmune diseases include rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, celiac disease, Hashimoto's thyroiditis, and the many other hard-to-classify syndromes of the 21st century. At their root they are connected by one central biochemical process, an immune imbalance. Your immune system gets confused and your own tissues get caught in a crossfire. Your body is fighting something - an infection, a toxin, an allergen even food, and somehow it redirects its hostile attack on your own tissues. This immune confusion results from what is referred to as molecular mimicry: when the invader's structure is very similar to the structure of our own tissue. Interestingly, autoimmune disorders occur almost exclusively in developed countries. People in poor nations without modern amenities like running water, flush toilets, washing machines, and manicured backyards don't get these diseases. If you grew up on a farm with lots of animals, you are also less likely to have any of these inflammatory disorders. Playing in the dirt and being exposed to bugs and infections trains your immune system to recognize what is foe and what is "you." Stress has a huge impact on your immunity, weakening your ability to fight infections and increasing your chances to develop allergies and autoimmunity.Autoimmune diseases when taken all together are a huge health burden. Unfortunately, many of the conventional treatments available can make you feel worse. When used selectively, these drugs can help people get their lives back. But they are not a long-term solution. Anti-inflammatory drugs and immune suppressants may lead to multiple side effects. They shouldn't be the end of treatment, but a bridge to cool off inflammation while the root cause of the disease is found and addressed.Naturopathy sees you as a whole, not as a machinery with separate parts. No matter what part of your body is under attack by your immune system, the solution is one and the very same: you need to find the root cause and balance your immune system using a functional medicine approach, a new way of thinking about the underlying causes and imbalances in chronic disease.You are also a unique individual a mixture of your genetic makeup, your history and your environment, therefore the only real solution is finding and addressing your specific cause, ridding your body and your environment of anything that may drive your condition, healing your damaged tissues by supplying your body with immune-balancing nutrients and powerful botanicals. The journey is long, it is not easy, but it leads to quality of life without side effects and halts the spread of autoimmunity to new tissues.

See the rest here:
Healthy Living: Autoimmunity the confused immune system - Limerick Leader

Read More...

Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology – Yahoo…

November 7th, 2021 1:55 am

Data Presented at ASH Underscores the Potential of the Smart-Immune Platform That Can Generate ex-vivo T- cell progenitors and NK- Cells for the Treatment of Primary Immunodeficiencies, and Cancers

PARIS, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T-cell medicine company utilizing its proprietary ex-vivo biomimetic thymus in a dish technology to develop allogeneic T-cell progenitors Smart-101 (ProTcell) for rapid immune reconstitution, announced today the presentation of clinical data and preclinical research at the 63rd annual meeting of the American Society of Hematology (ASH), taking place December 11-14 in Atlanta, Georgia. Preliminary data in these abstracts became available on the ASH conference website 9:00 AM ET yesterday. Recently, Smart-Immune has also announced the commencement of its first US clinical trial using its T-cell progenitor product (Smart-101) for the treatment of patients with AML and ALL who receive allogeneic hematopoietic stem cell transplant (allo-HSCT).

For a young company like ours, the selection of abstracts at a prestigious hematology conference like ASH is a recognition of the potential of our platform technology to uniquely and selectively generate large numbers of T- and/or NK-progenitors with the purity and reproducibility necessary for clinical use, commented Karine Rossignol, the Chief Executive Officer and co-founder of Smart-Immune. These abstracts selected represent a decade of research by my co-founders Drs. Marina Cavazzana and Isabelle Andre to create a short and elegantly simple 7-day culture system to generate lymphoid progenitors allowing a fast (within 100 days instead of 1-2 years) a polyclonal reconstitution of a fully functional immune system able to fight cancers and infections, changing drastically the prognosis of patients. With widespread applicability across primary immunodeficiencies, and hematological cancers, and three clinical trials launched, Smart-Immune is the first company to bring allogenic human progenitor cells into clinical development.

Story continues

Abstracts accepted at ASH include:

1)

Rapid and Safe T Cell Immune Reconstitution By T Cell Progenitor Injection Following Haploidentical Transplantation for Severe Combined Immunodeficiency (SCID).

Presenter: Despina Moshous, Hospital Necker Enfants Malades

Session Name: 704. Cellular Immunotherapies: Clinical: Poster I

Session Date: Dec 11th, 2021

Session Time: 5:30 PM - 7:30 PM

Room: Georgia World Congress Center, Hall B5

Abstract Synopsis: Severe Combined Immunodeficiency (SCID), is a severe form of primary immunodeficiency, responsible for the death, within the first few months of life, if not treated with HSCT. In the absence of an HLA-identical HSC donor, an urgent haploidentical HSCT is proposed to newborns with Severe Combined Immunodeficiency (SCID). The authors describe how the Delta-4 ligand based, culture system, that is at the core of the Companys invention, can be used to generate the earliest CD7+ T-cell progenitors (Smart-101) from such a haploidentical donor. Patient outcomes for two SCID babies being treated in the ongoing Smart-Immune phase 1/2 trial in SCID, who receive Smart-101 after allogeneic HSCT is discussed. Available data indicate that when Smart-101 is used at the optimal window of time in the early weeks after birth, rapid immune reconstitution with CD3+, CD4+, CD8+ and CD19+ T-cells may result in freedom from infections and GvHD and can be lifesaving for such SCID babies. These preliminary results deserve further investigation, which will be performed as part of our ongoing clinical study.

2)

Ex Vivo Production Of Large Numbers Of Genetically Modified NK Cells From Cord Blood Or Mobilized Peripheral Blood CD34+ Cells Using Notch Ligand Delta-Like 4 Culture System

Presenter: Ranjita Devi Moirangthem, Smart-Immune SAS

Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster II

Session Date: Dec 12th, 2021

Session Time: 6:00 PM - 8:00 PM

Room: Georgia World Congress Center, Hall B5

Abstract Synopsis: In this research the authors extend the utility of the Companys proprietary Delta-4 ligand based, feeder free, culture platform from generating not just pure allogeneic T-cell CD7+ progenitors (Smart-101), but also being able to generate T-cell free, CD56+ NK-cells (Smart-103) when culture conditions are modified to be NK-conducive. Expansion of these NK-progenitors result in NK populations with normal surface markers, gene expression patterns and cytotoxicity seen in NK cells immunoselected from human beings. Allogeneic NK-therapy is at its infancy but provides many advantages over T-cell therapy in it being free from graft-versus-host disease and downstream cytokine storm in the recipient. Moreover, the Companys NK-cells are also easily gene modifiable such that the transgene is robustly expressed in the NK population, paving the way for possible future CAR- NK development expanding our technology to both lymphoid populations, i.e., T and NK cells.

At Smart-Immune, we are first and foremost focused on validating that our first cell-therapy product, which is our early progenitor T-cells (Smart-101) devoid of any form of genetic engineering, is of easy access and safe to patients in both the short-term and long-term, said Dr. Marina Cavazzana, co-founder and Chief Medical Officer of Smart-Immune. Smart-101 has to be safe and effective in what it is intended to do i.e., shorten the lymphoid immunodeficient period from 18 months to 3-6 months, benefiting infection, graft versus host (GvHD) and relapse rates, and possibly augmenting survival. Proving this in 2022-2023 will pave the way for our next phase of clinical programs starting early 2024 using CAR-ProTcell where our progenitor T-cells could bear efficient transgenes to fight cancers.

A description of all three US and European clinical trials using Smart-Immunes progenitor populations can be found on the Companys website: Smart-Immune.com

To learn more about the US clinical trial for Smart-101 in pediatric and adult leukemia, please refer to: ClinicalTrials.gov (Trial Identifier: NCT04959903)

About Smart Immune:Smart Immunes mission is to make T-cell therapy accessible and affordable to all patients and, through its groundbreaking ProTcell platform, has developed clinical stage T-cell progenitors designed to improve prognosis for patients affected by malignant blood diseases or rare primary immunodeficiencies. The company is utilizing its unique ex-vivo biomimetic thymus in a dish technology to culture specific T-cell progenitor subpopulations at clinical scale and use them for cell or gene therapy. The company was founded in 2017 by Dr Isabelle Andr, Karine Rossignol, and Dr Marina Cavazzana from Hpital Necker-Enfants Malades AP-HP, a pediatric hematologist and a pioneer in vector-based therapies and hematopoietic stem cell treatments.

About ProTcell:The Smart Immune ProTcell platform generates allogenic T-cell progenitors that provide fully functional polyclonal T-cells within 3 months following an allogeneic HSCT while also reducing GvHD, infections and relapses thereby reducing morbidity and mortality and improving the benefice risk ratio for allogeneic medicine. When infused, ProTcell progenitors migrate to the patients thymus where they expand, are selected, and then differentiate, resulting in fully functional T-cells, tolerant to the patients own immune system and reactive to viral, fungal, and malignant antigens. ProTcell has been accepted by the FDA as an Investigational New Drug (IND) for Acute Lymphocytic Leukemia (ALL) and Acute Myelocytic Leukemia (AML) and has also been granted fast track designation under its expedited program for serious conditions like SCID. In 2021, the FDA granted orphan drug designation for ProTcell as a treatment to enhance cell engraftment in patients receiving hematopoietic stem cell transplant (HSCT) including hematologic malignancies and all forms of primary immunodeficiencies. ProTcell is currently being studies in two clinical trials in Europe, with two in the U.S. expected to start in Q4 2021. To learn more, please visit http://www.smart-immune.com

Media/Investor Contact

Media Contact

Jason Wong

Clare Evans

Blueprint Life Science Group

Smart Immune

jwong@bplifescience.com

clare.evans.ext@smartimmune.com

Read the original here:
Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology - Yahoo...

Read More...

A dangerous parasite could be used to treat cancer new research in mice – The Conversation UK

November 7th, 2021 1:55 am

A parasite commonly found in cats faeces might one day help treat cancer. My colleagues and I have discovered that the parasite that causes toxoplasmosis a condition that can be harmful to pregnant women and those with a suppressed immune system might be useful at destroying cancer tumours. At least, thats what our study in mice suggests.

For many years now, researchers have been looking at how they can use the bodys immune system to treat cancer known as immunotherapy. This is because, alongside protecting us from the harmful effects of bacteria and viruses, our immune system also rids the body of abnormal cells, such as cancer cells. But sometimes these cancerous cells and tumours can develop techniques for evading the bodys immune system, which means that the immune system wont kill them, and theyll be allowed to grow and replicate.

One type of immunotherapy is immune checkpoint blockade therapy. Our immune system contains a number of so-called immune checkpoints that prevent it from destroying healthy cells. But cancer cells can also avoid destruction by taking advantage of this on/off switch. The checkpoint can shut down immune cells called T cells and suppress the immune response. This is how some tumours are able to avoid being destroyed by the immune system.

Immune checkpoint blockade therapy works by blocking the checkpoint proteins from binding with their partner proteins and sending the off signal. This means that the cancer cells will become visible to the T cells, which can then go about destroying the tumour.

While immune checkpoint blockade therapy has shown promise in treating many types of cancer including lung cancer and melanoma this type of therapy, and many other immunotherapy treatments, dont work very well on so-called cold tumours. These difficult to treat tumours are surrounded by cells that suppress the bodys immune response, which means immune cells wont know how to attack it. Types of cancers where cold tumours are common include breast, ovary and prostate cancers.

But our latest research has discovered a method that could improve the treatment of these cold tumours and it involves using the parasite that causes toxoplasmosis, a relatively common condition that people catch from the faeces of infected cats or infected meat. While its typically harmless and often only causes mild flu-like symptoms, it can be serious in pregnant women and those who have a compromised immune system.

Toxoplasmosis is caused by the Toxoplasma gondii parasite. The reason we chose T. gondii is because it is very infectious and has been shown to infect many species of warm-blood animals including humans. The pathogen is also very tough, secreting proteins that prevent the bodys immune system from acting ultimately ensuring its own growth, replication and survival. We figured that all these attributes would allow T. gondii to trigger a strong immune response if administered directly into a tumour in the hope that would be enough for the immune system to kill the cancer.

Using the gene-editing technology Crispr, our team engineered a strain of Toxoplasma gondii that lacked the protein that causes disease. We then injected this mutant strain directly into melanoma tumours in mice. We later tested it on colon and lung cancer tumours as well.

We were able to show that injecting the live parasite directly into a cold tumour was able to trigger a strong immune response in mice. We were also able to show that even nearby tumours, which hadnt been injected, had an increased immune response.

While previous studies have shown that Toxoplasma gondii can be used to treat tumours in mice, our study took this finding one step further. We showed that when this engineered parasite was used alongside immune checkpoint blockade therapy, tumour growth was significantly suppressed. The eight mice given dual therapy in the early stages of melanoma saw their tumours shrink significantly, whereas treatment with only immune checkpoint blockade therapy failed to cause any regression in the injected tumours in mice.

We also showed that the dual treatment was far more effective at not only shrinking tumours but also improving the survival rate of mice when compared with using immune checkpoint blockade therapy alone. All eight mice who only received immune checkpoint blockade therapy died within 39 days while seven out of eight mice who received the dual treatment were still alive after 60 days. We also saw an increase in a number of different types of helpful immune cells which ultimately improved the response of melanoma tumours in particular to treatments.

Our research joins a body of evidence that parasites including the canine tapeworm Echinococcus granulosus can work against different types of cancer. Bacteria, viruses and bacteriophages (viruses that attack bacteria), are also being trialled as potential cancer treatments.

Its important to note that this study is only in mice, and it will take many years and many more studies before we know if this therapy works in humans. Nevertheless, its an exciting step in the right direction and adds to the growing evidence base that pathogens might be helpful tools in our fight against tough-to-treat cancers.

Read more:
A dangerous parasite could be used to treat cancer new research in mice - The Conversation UK

Read More...

Unexpected Antibody Type Discovered In Individuals With Malaria; New Insights Into Immune Response Against Disease [Study] – IBTimes India

November 7th, 2021 1:55 am

Facts about RSV and HMPV

When it comes to mosquito-borne diseases, malaria is among the worst. It claims thousands of lives annually worldwide and is widely considered an infection of the blood and liver. Also, the antibodies produced in response to the disease are well documented. However, scientists have reported the detection of an unexpected antibody produced against malaria in infected individuals: one that is made primarily in response to infections of the mucous membranes of different organs.

Through a multi-institutional study, researchers discovered the production of IgA (Immunoglobulin A) antibodiesthat are produced when the mucous membranes of organs such as the lungs are infectedin individuals infected with malaria. The study also found that the levels of IgA produced in children and adults in response to parasitic infection varied significantly.

"Not much had been done to study IgA antibodies in malaria infections, because people had not thought that they were important. Yet, because we were not looking for them, we may have missed a whole avenue of research that we can now explore," said Dr. Andrea Berry, corresponding author of the study, in a statement. The findings were published in the journal NPJ Vaccines.

Female anopheles albimanus mosquito (Representational Picture)Pixinio

Malaria is caused in human beings by five parasitic protozoa from the Plasmodiumfamily. They are transmitted through the bites of infected female Anopheles mosquitoes that serve as the primary vectors. Two of these protozoansPlasmodium falciparumand Plasmodium vivaxpose the biggest threats.

Several complications arise due to malaria. This includes damage to organs such as the kidneys and the liver, and can also result in the rupturing of the spleen. According to the World Malaria Reportreleased by the WHO in 2020, there were 229 million cases of malaria in 2019. The estimated number of deaths due to malaria was approximately 409,000 in 2019. Children below the age of five accounted for 67 percent (274,000) of all malaria deaths.

Different types of antibodies are produced by the immune system to help fight infections, and also to prevent reinfection. In older research, the authors had studied other antibody responses in patients with malaria. As expected, antibodies IgG (Immunoglobulin G), which is the most abundant antibody, and IgM (Immunoglobulin M), an antibody that appears during the initial phases of several infections, were detected.

Colorized scanning electron micrograph of red blood cell infected with malaria parasites, which are colorized in blue (Representational Picture)Flickr/ NIH Image Gallery

However, they also chanced upon an unexpected antibodyIgA (Immunoglobulin A). This was uncharacteristic as these antibodies are mostly produced in response to infections in the mucous membranes in areas such as the intestines, lungs, and vagina, among others. Therefore, the researchers chose to conduct a follow-up study to investigate additional samples for confirming their discovery and to scrutinize more groups of participants.

For the current study, the team examined antibody responsesboth IgG and IgAagainst P. falciparum in blood samples obtained from participants constituting three cohorts. The first group was composed of 32 individuals who had been infected through mosquito bites. Blood samples were collected on 1, 15, and 29 days post-infection.

The second group consisted of 22 volunteers who were challenged with the infection through direct intravenous (IV) introduction of P. falciparum. Blood samples were collected on 1, 29, and 57 days post-infection.

Red Blood Cells (Representational Picture)Wikimedia Commons

In addition to the two volunteer groups, the authors also collected samples from 47 childrenbetween the ages of one to sixliving in Mali, West Africa. These children were part of a malaria vaccine trial and their infections were naturally acquired during the course of the study.

Through their analysis, the researchers learnt that adult participants infected with malaria had high levels of IgA antibodies. The vaccine trial group consisting of Malian children exhibited a reduced prevalence of IgA antibodies. They also showed variability in the antigen specificity. However, ten children from the cohort had IgA antibody levels that were similar to those observed in adult participants.

The team also noted that patterns of IgG response were different between the three groups. Nevertheless, despite these variations, IgG antibodies were found to increase among all three cohorts. One question, however, remains to be answered: What leads to the development of IgA antibodies in malaria patients?

A mosquito biting a person (Representational Picture)Pxfuel

"We do not know what triggers the IgA antibodies to develop, but we think it happens early in a malaria infection. Some people think that the response might happen when the mosquito injects the parasiteinto the skin. Interestingly, some of our participants were not bitten by mosquitoes because their malaria infection was delivered intravenously, so there are probably additional triggers for IgA development," stated Dr. Berry.

It is not certain why the levels of IgA in children were not universally high. Dr. Berry averred that several reasons could be responsible for the differing levels of IgA. "Perhaps, children's immune systems respond differently to the parasite than adults do, or it is possible that IgA antibodies are only created during the first malaria infection," she posited.

Children (Representational Picture)Stocksnap.io

Deliberating on other potential reasons, Dr. Berry explained that the team was aware that the adult participants had received their first infection. However, it was not known whether the children in the vaccination trial had been infected previously.

While the timing of the infections and collection of samples among the adult volunteers was uniform, it was not the case among the child cohort. This was because their malaria infectionsoccurred coincidentally during the course of the study.

Dr. Berry added that tests can now be carried out to ascertain whether IgA antibodies prevent malaria parasites from entering red blood cells or the liver. She also said that the proteins which are targeted by IgA antibodies can be investigated and it can be gleaned whether they can be used in vaccines.

See more here:
Unexpected Antibody Type Discovered In Individuals With Malaria; New Insights Into Immune Response Against Disease [Study] - IBTimes India

Read More...

New Preventative Medicine Facility Wraps Work in NYC – Healthcare Construction and Operations News

November 7th, 2021 1:54 am

By HCO Staff

NEW YORK CITYWare Malcomb, an award-winning international design firm, recently announced construction is complete on Princeton Longevity Center, a preventive medicine facility located at 1 World Trade Center. Ware Malcomb provided the interior architecture and design services for the project.

The 10,000-square-foot facility is a new build-out that includes a 2,000-square foot-imaging-diagnostic licensing suite, including advanced technology imaging rooms and a CT scan room. The space also includes a reception area, a lounge, individual patient rooms, exam rooms, offices, and a fitness room. The design is hospitality-focused and mirrors the aesthetic established at their Princeton, New Jersey location.

Princeton Longevity Center is extremely patient-centric in all of their decisions, said Marlyn Zucosky, Regional Director, Interior Architecture & Design for Ware Malcomb. We were pleased to work closely with them to design a facility to enhance their patients experience and wellness. The result is a highly-functional, relaxing and beautiful space in one of the worlds highest-profile buildings.

At the entrance to the suite, a virtual receptionist assists guests with check-in. The inviting lounge offers spectacular views from the 71st floor of the 1 World Trade Center and incorporates wood-look luxury vinyl tile flooring, as well as a curved reception desk with backlit features. A custom hand-woven rug, a unique light fixture and a custom millwork coffee bar add a hospitality vibe to the spacious waiting area.

Individual patient rooms provide guests with a private space while they spend the day at Princeton Longevity Center and include computers, showers and a relaxing lounge atmosphere. The exam rooms and doctor offices, which also provide views of the city, incorporate calming colors. The rich tones of the design color palette are a dramatic contrast to the natural light provided by floor-to-ceiling windows.

The general contractor was Icon Interiors, Inc. The project achieved LEED Gold certification, a requirement of all 1 World Trade Center tenants. This is Ware Malcombs second project for Princeton Longevity Center; the first was their Princeton, NJ location, completed four years ago. Princeton Longevity Center is a leader in the preventive medicine market, offering the most advanced technology services and serving C-suite clientele with comprehensive medical evaluations.

Here is the original post:
New Preventative Medicine Facility Wraps Work in NYC - Healthcare Construction and Operations News

Read More...

MPD working with faith-based leaders to fight violent crime – FOX13 Memphis

November 7th, 2021 1:54 am

MEMPHIS, Tenn. Across Memphis, there have been at least 270 homicides compared to 263 at the same time last year. With less than two months left in the year, the city is on pace to shatter last years record.

In an effort to slow things down, MPD is working on getting to the source of violent crime.

Faith-based leaders have partnered with law enforcement to offer resources. The goal is for officers not just to respond to crimes but also to stop them before they start.

Preventative medicine is the best form of medicine, said Pastor Ricky Floyd with Pursuit of God Church.

To cure a city plagued by violent crime, the Memphis Police Department has partnered with faith-based leaders to get to the root of the problem.

Couples counseling, trauma response, gang talk, domestic violence, conflict resolution. Those are some of the things problematic in our community, said Memphis Deputy Police Chief PaulWright.

Faith-based leaders, MPD, and the U.S. Attorneys Office are hosting the Better Community Summit Saturday. The aim is to connect attendees with experts who specialize in areas Wright described.

Young people have seen things happen in their community now that they dont quite understand.If they dont get that fixed, it may be a problem in the future, Wright said.

Floyd said this summit is vital to lift the community.

Sometimes people think no one is out there to help me. Theres a lot of help available, said Floyd.

The summit isSaturday from 10 a.m. to 2 p.m.at Pursuit of God Transformation Center in Frayser.

CLICK HERE TO DOWNLOAD

Trending stories:

2021 Cox Media Group

Read more from the original source:
MPD working with faith-based leaders to fight violent crime - FOX13 Memphis

Read More...

Cornell grad and lecturer touts benefits of plant-based diet – ithaca.com

November 7th, 2021 1:54 am

If there is one piece of advice that 87-year-old Dr. T. Colin Campbell would give to those looking to age well and stay healthier longer, it would be to change your diet to a plant based, whole food approach.

The idea of plant based eating has gained popularity in recent years, but it was first coined by Campbell back in 1978. The bestselling coauthor of The China Study (published in 2006) said it has been exciting to see it gain traction in the last several years.

Its interesting because the idea of a plant based diet possibly being the best and the way of the future is just beginning to take hold in the mainstream public, Campbell said.

His recommendation that most everyone can adopt a plant based diet and have it benefit their lives hinges on a discovery he made early in his career: that people do not need to eat animal protein in order for their bodies to get the protein they need.

For the son of a dairy farmer, this flew in the face of what he had believed growing up but the evidence that a plant based diet can prevent and, in the vast majority of cases, even reverse common American ailments like diabetes, high cholesterol and heart disease was so strong that he dedicated his career to researching it and publicly sharing his findings. He has also worked to shape public policy around health and nutrition and was the liaison to Congress for the medical research community in 1980 and 1981.

Campbell wasnt always interested in studying nutrition. He was completing his first year of veterinary school when he received a telegram from a well known Cornell Professor offering him a scholarship and research opportunity, which led him to complete his education at Cornell University and MIT in the field of nutrition, biochemistry and toxicology. During his time at Cornell, around 1965, he was tasked with coordinating an effort to aid malnourished children in the Philippines. It was believed at the time that the children needed more animal protein to be healthy, but what Campbell found instead was that the few children who came from families who were able to consume more animal protein had a higher rate of liver cancer than their peers.

I couldt quite believe what I was seeing, Campbell said. I had many students work in the lab on this question and over the years found that there is no need to consume animal food to get that protein. That is totally false.

Campbell spent a decade on the faculty of Virginia Techs Department of Biochemistry and Nutrition, then returned to Cornell in 1975, where he currently holds his endowed chair as a professor emeritus of nutritional biochemistry in the Division of Nutritional Sciences.

In recent years Campbell founded a non-profit organization on online learning in nutrition which recently developed, under the direction of Campbells daughter LeAnne Campbell, the program Plant Forward, which holds online workshops.

The workshops teach a simple philosophy that can be difficult to put into practice at first but pays great dividends if the individual can stick with it for a month or two, Campbell said.

The people who stay with it are often people who have a serious health problem or have a motivation, he said. Sometimes the effects are almost immediate.

People can see their blood sugar drop precipitously in one day, he said. Its amazing.

The key is to go all-in on the new diet. He likened it to quitting smoking just cutting down to one or two cigarettes per day or smoking on some days but not on others is not likely to lead to success in the longterm. But soon, Campbell said, this new kind of eating will become second nature and even enjoyable.

Youll all of a sudden discover you crave a salad, he said. Just eat vegetables, grains, nuts, and avocados for the oil and fat.

As much as possible, stay away from added oils and refined carbs, he added.

The effects of adopting a whole plant-based diet are striking, he said.

We can turn experimental liver cancer genes on with animal based protein and turn it off by eating a plant based diet, he said.

Campbells own father died of a heart attack when he was 70, and his wifes mother died of colon cancer when she was just 51. That motivated us to think about changing our diet, so we did, he said. His wife is 80 years old, and both are largely medication free other than a short period Campbell spent on medication to control his blood pressure.

Campbells first book, The China Study, came out of a partnership in the 1980s with researchers at Oxford University and the Chinese Academy of Preventative Medicine and sold nearly four million copies worldwide. Campbell followed that up with his second book, Whole, in 2013, which is focused on the science behind plant based eating.

In 2020 he published The Future of Nutrition: An Insiders Look at the Science, Why We Keep Getting it Wrong, and How to Start Getting It Right.

He still gives lectures and is involved with the online Plant-Based Nutrition Certificate in Partnership with eCornell. His research is the cornerstone of the 2011 documentary film Forks Over Knives, and his oldest son, Nelson Campbell, made another popular documentary on the topic called Plant Pure Nation.

Some advice that he received from his father that has guided him throughout his life: Tell the truth, the whole truth, and nothing but the truth. It is a philosophy that allowed him to question his original assumption that eating animals must be good for health.

The key is to be honest with yourself and check your own biases, he said. Thats really critical.

See original here:
Cornell grad and lecturer touts benefits of plant-based diet - ithaca.com

Read More...

Meet the Cork-born bread activist who has Goldie Hawn buying her loaves – Irish Examiner

November 7th, 2021 1:54 am

Karen ODonoghue has a goal: to cure everyone in Ireland of IBS. And, paradoxically, shes aiming to use bread to do it.

Already you can see the bands of gastroenterologists around the country tut-tutting at such a tall order.

Yet, ODonoghue should know a thing or two. In 2018 she was named Gut Specialist of the Year in the UK and she is currently a judge for the World Bread Awards.

Actress Goldie Hawn rates her anti-inflammatory bread so highly that she took ten loaves with her back to the US and claimed it cured both her and her sons Irritable Bowel Syndrome (IBS).

Ears perk.

Every system and organ in the body is dependent on the health of the gut microbiome so when you nourish the microbiome, it automatically nourishes the brain, says ODonoghue from her new bakery in Mayo.

Youll make better decisions in your life, have more energy, and youll enjoy better sex, she adds, with a twinkle.

Eyebrows raise.

Bread activism it kind of has a ring to it.

And this is the business ODonoghue is in, swapping prescriptive medicine for a food-led approach to managing and healing ones own body.

As the founder of the Happy Tummy Company in London in 2014, she is responsible for single-handedly pioneering a scientifically-developed range of breads aimed at alleviating IBS (her UK customers coined the term magic poo bread for how much it helped them), mental health issues, period and menopause pain, and, what she describes as functional rehab for both physical injury and trauma from illness.

The Happy Tummy Company was born out of a deep desire to help others, and in turn, out of illness.

Growing up in Cork where her parents ran a horticulture company, when ODonoghue was 10 years old her mother was diagnosed with cancer.

She vividly remembers the lightning bolt moment that would dictate the course of her future.

Growing up with a mother who had cancer and who ultimately died from it, I was very aware of the part food had to play in our overall wellbeing.

During the time of my mums cancer treatments I remember digging the soil with my dad, planting beech saplings, and I had this epiphany: when Im older Im going to create a brand thats all about food as preventative medicine.

Fast forward to 24-year-old Karen living in London.

Having spent most of her life battling with IBS, she found herself depressed and anxious.

The older I got and the more my IBS became an issue, I knew I needed to go back to that ambition I had as a little girl. Intuitively I always knew that food is medicine.

She started poring over scientific research papers to learn about the gut microbiome and discovered that our gut bacteria works to a specific mathematical equation: we should be eating 66% dietary fibre to 33% dietary protein and five grams of prebiotic fibre every day.

Based on this, she created her own formula (her father was a maths teacher they regularly discussed theorems at the dinner table) and applied it to the bread making process.

It was during this time that she discovered a gluten-free grain from Africa.

The star ingredient is teff, grown in Ethiopias highlands, which is high in protein, calcium and iron, along with prebiotic fibres and antioxidants, all of which stimulate the growth of good gut bacteria, reduce inflammation and nourish the lungs, brain, skin, and nervous system. Teff relieves bloating and constipation and also helps to balance hormone levels, stimulate digestion and strengthen bones.

After 18 months of a mad scientist-like existence in her London flat she developed a loaf of bread that would completely rid her of her IBS.

From having one bowel movement every three weeks, within a week she was doing two poos a day.

The shape of her tummy changed, her depression and anxiety disappeared and she started to feel alive again.

That loaf is now her best-selling Chia Teff Loaf, aka the magic poo bread

In 2014 she established her London bakery, The Happy Tummy Company (cue Goldie Hawn and many more high-profile followers) in Hackney and a school where she taught students how to use food both as preventative and prescriptive medicine.

The bread-making process started as a means to cure her own IBS but once the word got out, loaves were flying off the shelves like IBS-crusading hotcakes.

Last year, after 13 years in the UK, she decided to relocate the business headquarters to Westport in Mayo.

ODonoghue walks the talk. She beams of health and is genuinely positive, which is infectious to be around.

ODonoghue believes we need to pare back how we look at bread and start viewing our consumption of it primarily from a health perspective, and flavour as a secondary issue.

The reason bread has a branding problem, she believes, is because bakers are obsessed with the aesthetics of what they are making over nourishment, creating white, fluffy sourdough breads using commercial wheat.

Consumers, particularly those who have issues with gluten or coeliac disease, eat these breads and all of a sudden feel bloated, lethargic, and agitated. And thats not surprising.

You are eating a wheat that is not very natural.

The Chia Teff Loaf takes about three days to make and is packed with organic teff (so no herbicides or pesticides), sprouted buckwheat, walnuts, Brazil nuts, almonds, linseed, and chia seeds all expensive ingredients.

It costs 25 per loaf.

As a bakery we are not yet making money and Ive had to fight an industry that has brainwashed people into thinking that food can be cheap.

I know its generally not politically correct to go so hard on this organic way of eating because people will argue that it is elitist, privileged and only a certain percentage can afford organic food.

But when I had the bakery in Hackney we had loads of customers who were on the breadline buying our bread because they fundamentally understood the importance of organic, wholegrain food in their diet.

This month ODonoghue launches her 48-hour soaked wholegrain Chia Teff Loaf, aka the magic poo bread, to the Irish market on a nationwide delivery service.

She also runs baking classes at her school house, Teach Scoile, in Westport to educate people on the benefits of teff.

As a baker, she separates bread makers into two camps.

There are those who nourish, and there are those who feed, she says.

And Ive always wanted to nourish.

When I had that epiphany at 10 years of age I knew that this brand will be more of a vocation than a business.

What Im doing here is a vocation about preventative medicine to give every single person suffering with IBS access to food and education that works.

Link:
Meet the Cork-born bread activist who has Goldie Hawn buying her loaves - Irish Examiner

Read More...

Pfizer says pill cuts risk of severe Covid by 89% – RTE.ie

November 7th, 2021 1:54 am

A trial of Pfizer's experimental antiviral pill for Covid-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalisation or death for adults at risk of developing severe disease, the company said.

The results appear to surpass those seen with Merck's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalised for Covid-19 patients also at high risk of serious illness.

Full trial data is not yet available from either company.

Professor Luke O'Neill said the new drug is "very significant" because the manufacturer got 89% efficacy in their trial.

The Trinity immunologist added: "What that means is 9 out of 10 people wouldn't end up in hospital with Covid. If that turns out to be true once it's launched that would be remarkable.

He said this disease is an emergency and Pfizer is applying for emergency use in the United States with the FDA and also with the European Medicines Agency (EMA).

"Those agencies will look very closely at the data and the safety and they will be really under pressure now approve these drugs because an antiviral is a great extra weapon to use against this virus," Prof O'Neill said.

Separately, the Tnaiste has said a new antiviral oral pill for Covid will be a "very valuable weapon" and he hopes it can be approved by the EMA "quite soon".

Yesterday, the UK medicines regulator became the first to approve the drug 'Molnupiravir', for people who have had a positive Covid test and have at least one risk factor for developing severe illness, such as obesity, being over the age of 60, diabetes or heart disease, something Leo Varadkar said was "really encouraging".

Mr Varadkar said: "Once you are diagnosed you can take this tablet and it reduces by up to half the chances of you needing to be hospitalised, so that can really make a big difference.

"I hope the EMA will approve that quite soon, because you can never deal with a virus through vaccination alone, you need therapeutics too and you need preventative medicine.

"This is going to give us an extra weapon in our armoury and a very valuable weapon too," he added.

Pfizer will now submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the US Food and Drug Administration as part of the emergency use application it opened in October.

The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.

A spokesperson from Pfizer in Ireland said that the company's plant in Ringaskiddy "will support the global manufacturing and supply" of the drug, if it is given approval.

He said: "Pfizer has begun investing prior to regulatory authorisation in the manufacture of our potential Covid-19 oral antiviral candidate to help bring this potential treatment to patients as soon as possible.

"Pfizer's site in Ringaskiddy has a successful history of contributing to our manufacturing efforts."

We need your consent to load this rte-player contentWe use rte-player to manage extra content that can set cookies on your device and collect data about your activity. Please review their details and accept them to load the content.Manage Preferences

The planned analysis of 1,219 patients in Pfizer's study looked at hospitalisations or deaths among people diagnosed with mild to moderate Covid-19 with at least one risk factor for developing severe disease, such as obesity or older age.

It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalised and none had died by 28 days after treatment.

That compared with a hospitalisation rate of 7% for placebo patients. There were also seven deaths in the placebo group.

Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalised, compared with 6.7% for the placebo group, which included ten deaths.

Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.

"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective," said Annaliesa Anderson, head of the Pfizer programme.

The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.

"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients' lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of ten hospitalisations," said Pfizer Chief Executive Albert Bourla.

Infectious disease experts stress that preventing Covid-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.

Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.

Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus.

Merck has already sold millions of courses of the treatment, which was approved this week by UK regulators, to the US, the UK and others.

Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.

Pfizer is also studying whether its pill could be used by people without risk factors for serious Covid-19 as well as to prevent coronavirus infection in people exposed to the virus.

Read more:
Pfizer says pill cuts risk of severe Covid by 89% - RTE.ie

Read More...

The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm – Yahoo News

November 7th, 2021 1:54 am

A supporter of President of Brazil Jair Bolsonaro waves a box of ivermectin at a pro-government demonstration in Brasilia in May 2021. Andressa Anholete/Getty Images

The popularity of unproven anti-parasitic drug ivermectin as a COVID-19 treatment is surging.

Its use has roots in South America, where it was hyped by populist leaders citing debunked research.

"Nobody paid attention... now we see the same" in the US, a Peruvian official told Insider.

In May 2020, when the coronavirus was sweeping the South American nation of Peru, Dr. Patricia Garcia of the country's health ministry began receiving disturbing reports from the country's hospitals.

They detailed injuries not caused by COVID-19, but a drug people thought would help them: the anti-parasitic substance ivermectin.

"The kind of things they were telling was people that were coming with severe gastritis [stomach inflammation], and also pancreatitis, because they were taking the ivermectin in desperation," Garcia told Insider.

As the coronavirus continued to spread, people's faith in ivermectin as a way out of the crisis grew more fervent, said Garcia.

It would be almost a year before ivermectin would become widely discussed in the US, as a subset of Americans began to insist on receiving it.

The US demand for ivermectin surged as vaccination - the most effective COVID countermeasure - became increasingly politicized. Doctors strongly advise against taking it but, as of October 16, more than two-dozen lawsuits had been filed around the US from people demanding access to it.

"History is repeating," said Garcia. "Nobody paid attention about what was happening in Latin America and now we see the same situation."

A municipal worker sprays disinfectant past a street vendor at a market in Puno, Peru, near the border with Bolivia, on June 10, 2020. CARLOS MAMANI/AFP via Getty Images

In the Peru of May 2020, there were no vaccines, and ivermectin's rise was being driven by hope and desperation.

Pharmacies fast ran out of pills as thousands sought to obtain it, and a lucrative ivermectin black market emerged, as local media reported at the time.

Adherents recommended both that healthy people take ivermectin as a preventative, and that it be used to treat COVID-19 after infection.

Story continues

Many resorted to a stronger version of the drug, normally used to deworm horses. That form is taken by injection, and people who took it were left with serious skin lesions, said Garcia.

As the fervor spread, evangelical groups based in southern Peru injected 5,000 people from indigenous communities with the drug.

In some cities, including the capital, Lima, public health officials distributed the stronger, dangerous form of the drug to whole neighborhoods.

The belief that ivermectin could work against COVID-19 is almost as old as the pandemic, predating vaccines and even proper testing.

Almost two years later, there is still no conclusive evidence that ivermectin is effective against COVID-19, and it has been repeatedly debunked, including by the FDA in September.

It said that taking large doses of any kind of ivermectin is dangerous, and that humans should never take drugs intended for treating animals.

Carlos Chaccour, a researcher at the Barcelona Institute for Global Health, pointed to an obscure research paper in early 2020 which appeared to answer the desperate desire for a workable treatment.

The paper drew on data from Surgisphere Corporation, a small research group in Chicago, which published it in April 2020 seeing to establish a link between taking ivermectin and surviving COVID-19.

A pharmacist in Santa Cruz, Bolivia, with doses of ivermectin. Rodrigo Urzagasti/picture alliance via Getty Images

The researchers, who also touted hydroxychloroquine, said the paper's basis was data from thousands of hospitals around the world. Their research was published by top-tier medical journals including The Lancet and The New England Medical Journal.

But doubts soon emerged the authenticity of Surgisphere's data, the credentials of its team, and the methodology they used.

The Lancet and The New England Medical Journal retracted the study after a backlash from the scientific community and an investigation by The Guardian. But by then, said Chaccour, the damage was done.

In summer 2020, government officials in Peru, Bolivia, and Guatemala made ivermectin part of their COVID-19 strategies, often citing the retracted study as evidence.

Chaccour told Insider that the drug was embraced so readily because it seemed to present a simple solution, was relatively cheap, and was already widely used in the region.

He noted that a danger of the drug - perhaps worse than its adverse effects - was that people who believed it to be effective against COVID-19 were more likely to ignore actions that actually work.

"One of the risks of ivermectin is not just the safety, but the hazard of people not using masks or not getting vaccines or not doing social distancing because they think they are protected," he said.

As a second wave of the coronavirus hit South America in the latter half of 2020, ivermectin became more popular still. The city of Cali in Colombia handed it out to all of its COVID patients in late July. Weeks later the state of Chiapas in Mexico followed suit.

In Brazil, South America's most-populous country, the drug was endorsed by the country's populist president, Jair Bolsonaro, and by his allies at a regional and national level.

But it wasn't just politicians. They were riding a wave of social-media misinformation that was still spreading. In groups on Facebook and WhatsApp, misinformation about ivermectin was being shared by millions, experts told Insider.

Among its influential promoters was COMUSAV, a group of renegade medics based in Bolivia, whose core product was a kind of industrial bleach promoted as a miracle cure for a vast array of ailments that included COVID-19.

They pushed ivermectin to their followers across the continent on their Facebook pages, which had tens of thousands of followers.

(Many of the group's pages were removed following an investigation by Insider in March 2021.)

A data analyst, Juan Chamie, was among those who helped to bring the enthusiasm for ivermectin from the populists of South America to their equivalents in the US, experts told Insider.

Chamie claimed to have data showing lower COVID-19 mortality in parts of South America where public health authorities approved ivermectin.

But Chaccour and data scientist Joe Brew have said his analyses are misleading, and ignore other factors that could explain the differences.

"Just because things are associated does not necessarily mean that one thing causes the other," they said.

That hasn't stopped Chamie's analyses being shared widely, until his account was suspended by Twitter.

Among those taking note was Laura Ingraham, primetime host of Fox News' show "The Ingraham Angle."

In December 2020 Ingraham posted a graph of data attributed to Chamie to her 3.8 million followers.

It purported to show a reduction in COVID-19 cases, comparing areas of Chiapas, Mexico, where officials did and did not distribute ivermectin.

Chaccour said that, as with Chamie's other claims, the decrease could be coincidental or due to other factors.

Ingraham already had a history of promoting ivermectin. As far back as March 2020, Ingraham had tweeted about the Surgisphere research that was later debunked.

Chaccour believes that Ingraham's advocacy was a tipping point for ivermectin in the US.

Progressive campaign group Media Matters noted that Ingraham's enthusiasm extended to her widely-viewed Fox News show.

In two episodes in December 2020, Ingraham claimed that medical authorities were conspiring to suppress the substance and ignoring evidence of its effectiveness. Andrew Lawrence, a Media Matters staffer, told Insider that Ingraham was "definitely the leader" among network hosts promoting the substance.

A Fox News spokesperson said in Ingraham's defense that she never explicitly told viewers to take the drug.

In comments to The Washington Post, Ingraham criticized attempts to "silence" scientists with unorthodox messages. "Just like the scientific consensus, the medical consensus is evolving. It changes," she sad.

Chamie also formed contacts with the Front Line Critical Care Alliance (FLCCA), a group of US medics who were influential in pushing ivermectin in the US, as detailed in a September investigation by Insider's Hilary Brueck.

Chamie describes himself as a senior data analyst for FLCCA on his LinkedIn page, and the group cites his research on its website.

The group has been instrumental in brokering ties between the pro-ivermectin movement and Republican lawmakers who promoted the drug.

Last December, Dr Pierre Kory, a member of the group, testified before the US Senate about ivermectin in what one critic, Brown University dean Dr. Ashish Jha, described in The New York Times as a "misinformation super-spreader event."

In a statement to Insider, the FLCCC defended its position on ivermectin, forwarding Insider a list of studies based on anecdotal evidence suggesting that ivermectin may be effective in reducing COVID-19 deaths. These studies are not considered conclusive by experts.

The group did not respond to questions regarding Chamie's research, and Chamie himself did not respond to requests for comment from Insider.

As proponents in the US clamored for wider use of ivermectin, in South America disillusioned officials were reversing their position.

In February Peru removed ivermectin from its COVID treatment protocol altogether because of the absence of evidence that it worked.

"It's incredible for me that we, a whole region, already went through this terrible situation in which lots of people have died," Garcia, the Peruvian official, told Insider.

"They were taking ivermectin because it was known to us, so it was easy for us. And it didn't work."

Read the original article on Business Insider

Read the rest here:
The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm - Yahoo News

Read More...

Prior poor mental health linked with higher rates of COVID- study – The Jerusalem Post

November 7th, 2021 1:54 am

Several studies have shown that the pandemic took a devastating toll on peoples mental health and impacted other psychiatric conditions, but a novel study looked at things from a different perspective.The investigation, conducted by Yale School of Public Health and published in the American Journal of Preventative Medicine, looked at US nationwide levels of mental health to establish that those with poor mental health prior to the pandemic have a greater likelihood of developing a COVID-19 infection.

Researchers used aggregated data from a survey conducted across 2,839 counties to conclude that between 2010 and 2019, a total of 2,172 counties (77%) experienced significant increases in the average number of poor mental health days, including depression, stress and problems with emotions.

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });

Further research revealed that more days of poor mental health in 2019 had a robust association with the rate of COVID-19 infections in 2020, leading researchers to believe that the pandemic did not cause new mental health problems, but rather revealed previously ignored issues.

Analysis revealed that poorer mental health days and COVID rates were driven by a few states-- Arizona, Montana, and Nevada.

Lead investigator Yusuf Ransome expressed hope that the study will encourage conversation about the urgency of mental health care.

We call for policies that strengthen surveillance systems to better capture a range of mental health outcomes in the population, address social inequalities that give rise to poor mental health, and [increase] funding to create, sustain and equitably distribute mental health resources, including wellness care centers across US communities," he said.

Ransome added that the idea for the study was inspired by the height of the pandemic.

"Only a handful of studies examining small fragments of the population had considered the possibility that poor mental health could be contributing to a higher burden of infection rather than vice versa," he said. "We wanted to examine whether these relationships also existed in the general population, address the lack of studies with an ecological-level focus, and produce evidence to strengthen calls for interventions.

Continue reading here:
Prior poor mental health linked with higher rates of COVID- study - The Jerusalem Post

Read More...

Page 171«..1020..170171172173..180190..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick